-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – STX-478 in Breast Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. STX-478 in Breast Cancer Drug Details: STX-478 is under development for the treatment of solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – STX-478 in Gynecological Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. STX-478 in Gynecological Cancer Drug Details: STX-478 is under development for the treatment of solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – STX-478 in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. STX-478 in Solid Tumor Drug Details: STX-478 is under development for the treatment of solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – STX-478 in Head And Neck Cancer Squamous Cell Carcinoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.STX-478 in Head And Neck Cancer Squamous Cell CarcinomaDrug Details: STX-478 is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – STX-478 in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. STX-478 in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) Drug...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Arbaclofen in Autism Spectrum Disorder (ASD)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Arbaclofen in Autism Spectrum Disorder (ASD) Drug Details:Arbaclofen (STX-209) is under development for treatment of fragile...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Resveratrol in Alzheimer’s Disease
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Resveratrol in Alzheimer's DiseaseDrug Details: Resveratrol is under development for the treatment of Alzheimer's disease. It...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MRX-8 in Gram-Negative Bacterial Infections
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.MRX-8 in Gram-Negative Bacterial InfectionsDrug Details:MRX-8 is under development for the treatment of multi-drug resistant gram...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BNT-142 in Non-Small Cell Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BNT-142 in Non-Small Cell Lung Cancer Drug Details: BNT-142 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Pidnarulex in Prostate Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Pidnarulex in Prostate Cancer Drug Details: Pidnarulex is under development for the treatment of relapsed/refractory haematological...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Balstilimab in Ovarian Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Balstilimab in Ovarian Cancer Drug Details: AGEN-2034 (balstilimab) is under development for the treatment of metastatic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – APG-1387 in Blood Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. APG-1387 in Blood Cancer Drug Details: APG-1387 is under development for the treatment of advanced...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Vusolimogene Oderparepvec in Merkel Cell Carcinoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Vusolimogene Oderparepvec in Merkel Cell Carcinoma Drug Details: RP-1 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Rituximab Biosimilar in Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Rituximab Biosimilar in Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma) Drug Details:Rituximab (Hanlikangt,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Spartalizumab in Anal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Spartalizumab in Anal Cancer Drug Details: Spartalizumab (PDR-001) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Spartalizumab in Pancreatic Ductal Adenocarcinoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Spartalizumab in Pancreatic Ductal Adenocarcinoma Drug Details: Spartalizumab (PDR-001) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Ligufalimab in Small-Cell Lung Cancer
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Ligufalimab in Small-Cell Lung Cancer Drug Details: Ligufalimab is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Sacituzumab Govitecan in Muscle Invasive Bladder Cancer (MIBC)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Sacituzumab Govitecan in Muscle Invasive Bladder Cancer (MIBC) Drug Details: Sacituzumab govitecan (Trodelvy) is a...
-
Company Profile
![]()
MaxCyte Inc – Company Profile
MaxCyte Inc (MaxCyte) discovers, manufactures, and commercializes cell-based medicines. The company’s products include MaxCyte STX, MaxCyte VLX, MaxCyte GT, ExPERTATx, ExPERTGTx, ExPERTSTx and ExPERTVLx scalable transfection systems, which use the flow electroporation technology for engineering of cells. It is investigating MCY-M11 IP, a mesothelin-targeted therapy for treating ovarian and peritoneal mesothelioma, and MCY-M11 IV therapy for undisclosed solid tumors. MaxCyte provides insourcing services such as instrument training, follow-on experimentation and others. The company developed CARMA, a proprietary technology platform for...
Add to Basket -
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – STX-100
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry STX-100 Drug Details STX-100 is under development for the treatment of hand, foot and...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.